FindTrial
Sign In

A retrospective study: venetoclax-based therapy for patients with myeloid sarcoma

A retrospective study: venetoclax-based therapy for patients with myeloid sarcoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500102899
Enrollment
Unknown
Registered
2025-05-21
Start date
2020-01-01
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myeloid sarcoma

Interventions

Venetoclax:None

Sponsors

The First Affiliated Hospital of Xiamen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Myeloid sarcoma was diagnosed according to the 2016 World Health Organization (WHO) classification of hematological malignancies. 2.Patients who had been treated with venetoclax for more than 2 weeks.

Exclusion criteria

Exclusion criteria: VEN duration was less than 2 weeks.

Design outcomes

Primary

MeasureTime frame
ORR;—

Countries

China

Contacts

Public ContactYiming Luo

The First Affiliated Hospital of Xiamen University

luoyimingxm@126.com+86 592 2137318

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026